2014 Fiscal Year Final Research Report
Examination for immunological effects of oncolytic Sendai virus on malignant brain tumor
| Project/Area Number |
23701109
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Chiba Cancer Center (Research Institute) |
|---|
Principal Investigator |
HASEGAWA Yuzo 千葉県がんセンター(研究所), 医療局 脳神経外科, 医長 (60436409)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Keywords | Oncolytic virus / Glioblastoma / dendritc cells / gene therapy / immunotherapy |
|---|
| Outline of Final Research Achievements |
Malignant brain tumor is highly invasive and intractable. Urokinase-targeted oncolytic Sendai virus vector, “BioKnife”, is one of promissing new therapeutic tools that possesses powerful oncolytic ability, we previously reported. We examined for immunological effects of this BioKnife armed interferon β, “BioKnife-IFNβ” in this study. Dendritic cells secreted high level of tumor necrotic factor α and interleukin-12 when they were cultured with 9L tumor cells infected by BioKnife, especially BioKnife-IFNβ. Rat malignant brain tumor cell line, 9L, is usually expresses low level of major histocompatibility complex class I and expression of this antigen was increased by BioKnife, especially BioKnife-IFNβ. This effect was not only observed in infected tumor cells but also non-infected cells, interestingly. Induction of cytotoxic T cells was actually detected in rats bearing brain tumor treated with BioKnife-IFNβ. This immuno-modulating BioKnife-IFNβ is very promising.
|
| Free Research Field |
Neurological surgery
|
